A Phase II Study to Investigate the Efficacy and Tolerability of Vorinostat in Patients Suffering From Advanced, Metastatic Soft Tissue Sarcoma.

Trial Profile

A Phase II Study to Investigate the Efficacy and Tolerability of Vorinostat in Patients Suffering From Advanced, Metastatic Soft Tissue Sarcoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs Vorinostat (Primary)
  • Indications Soft tissue sarcoma
  • Focus Therapeutic Use
  • Acronyms SAHA-I
  • Most Recent Events

    • 01 Aug 2017 Results of pharmacokinetic/pharmacodynamic analysis (n=10) published in the Cancer Chemotherapy and Pharmacology
    • 28 Jun 2016 Results published in the European Journal of Cancer
    • 28 Jul 2012 Planned end date calculated from estimated duration in European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top